☆ 4.7 Editorial Material

Should We Increase GFR with Bardoxolone in Alport Syndrome?

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)

Get Full Text
Add to Collection

Journal

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume 29, Issue 2, Pages 357-359

Publisher

AMER SOC NEPHROLOGY
DOI: 10.1681/ASN.2017101062

Keywords

-

Categories

Urology & Nephrology

Funding

  1. Merck
  2. Pfizer
  3. Novartis
  4. Bayer
  5. Boehringer Ingelheim
  6. Medical Research Council [MC_U137686853, MC_UU_12026/5, MC_UU_12026/6] Funding Source: researchfish
  7. MRC [MC_UU_12026/6, MC_UU_12026/5, MC_U137686853] Funding Source: UKRI

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.